(9ci)-4-氯-7-氟-1H-咪唑并[4,5-c]吡啶 | 405230-97-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: (9ci)-4-氯-7-氟-1H-咪唑并[4,5-c]吡啶
• 中文别名: 3H-咪唑并[4,5-C]吡啶-1,4-氯-7-氟
• 英文名称: 4-chloro-7-fluoro-imidazo[4,5-c]pyridine
• 英文别名: 4-chloro-7-fluoro-1H-imidazo[4,5-c]pyridine；4-chloro-7-fluoro-3H-imidazo[4,5-c]pyridine
• CAS: 405230-97-9
• 化学式: C₆H₃ClFN₃
• 分子量: 171.561
• InChiKey: DULUTDRRRDVDRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

反应信息

• 作为反应物：
  描述：

  (9ci)-4-氯-7-氟-1H-咪唑并[4,5-c]吡啶 在 硫酸氢铵 、 sodium methylate 、 六甲基二硅氮烷 作用下， 以 甲醇 为溶剂， 反应 2.5h， 生成 4-chloro-7-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine
  参考文献：
  名称：

  SYNTHESIS OF HALOGEN-SUBSTITUTED 3-DEAZAADENOSINE AND 3-DEAZAGUANOSINE ANALOGUES AS POTENTIAL ANTITUMOR/ANTIVIRAL AGENTS

  摘要：

  Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogen-substituted analogues (51 and 52), and 2',3'-dihalogen-substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7 muM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.

  DOI：

  10.1081/ncn-100108327
• 作为产物：
  描述：

  2-氯-4-硝基-5-氟吡啶氮氧化物 在 镍 三氟甲磺酸三甲基硅酯 、 硫酸 、 氢气 、 potassium nitrate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、275.79 kPa 条件下， 反应 3.0h， 生成 (9ci)-4-氯-7-氟-1H-咪唑并[4,5-c]吡啶
  参考文献：
  名称：

  SYNTHESIS OF HALOGEN-SUBSTITUTED 3-DEAZAADENOSINE AND 3-DEAZAGUANOSINE ANALOGUES AS POTENTIAL ANTITUMOR/ANTIVIRAL AGENTS

  摘要：

  Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogen-substituted analogues (51 and 52), and 2',3'-dihalogen-substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7 muM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.

  DOI：

  10.1081/ncn-100108327

文献信息

• [EN] TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE FURANE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018097944A1

  公开（公告）日：2018-05-31

  Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.

  式(I)和式(II)的化合物，其药用盐，任何上述化合物的立体异构体，或它们的混合物是APJ受体的激动剂，并且在治疗心血管和其他疾病方面有用。式(I)和式(II)的化合物具有以下结构：(I); (II)。中间体(V)也被要求。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021123294A1

  公开（公告）日：2021-06-24

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化或额颞叶痴呆。
• Novel nucleosides and related processes, pharmaceutical compositions and methods
  申请人：——

  公开号：US20040116362A1

  公开（公告）日：2004-06-17

  The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of 3-deazaguanosine. Compounds of the instant invention, including 4-Amino-6-fluoro-1-(&bgr;-D-ribofuranosyl)imidazo[4,5-c]pyridine and 6-Amino-7-bromo-1,5-dihydro-1-&bgr;- D -ribofuranosylimidazo[4,5-c]pyridin-4-one, have exhibited potent antiviral and anticancer activity in vitro. The compounds are also useful in the concomitant treatment of bacterial infections associated with viral infections such as AIDS.

  该发明提供了新颖的核苷和相关的工艺、药物组合和方法。这些新颖的核苷在抗病毒、抗肿瘤和抗菌应用中非常有用。该发明的首选实施例包括新型的2卤代、3卤代和2′,3′二卤代的3-去氨腺苷类似物，以及新型的3卤代的3-去氨鸟苷类似物。该发明的化合物，包括4-氨基-6-氟-1-(&bgr;-D-核糖呋喃基)咪唑[4,5-c]吡啶和6-氨基-7-溴-1,5-二氢-1-&bgr;-D-核糖基咪唑[4,5-c]吡啶-4-酮，在体外表现出强效的抗病毒和抗癌活性。这些化合物也在同时治疗与艾滋病等病毒感染相关的细菌感染方面非常有用。
• Direct SNAr amination of fluorinated imidazo[4,5-c]pyridine nucleosides: efficient syntheses of 3-fluoro-3-deazaadenosine analogs
  作者：Kandasamy Sakthivel、P. Dan Cook

  DOI：10.1016/j.tetlet.2005.03.190

  日期：2005.5

  This paper describes the ready preparation of 3,6-difluoro-3-deazapurine (4,7-difluoroimidazo[4,5-c]pyridine). This novel base was glycosylated under mild conditions using three different ribose sugar analogs. 3,6-Difluoro-3-deazapurine ribonucleoside analogs underwent direct SNAr amination reactions with liquid ammonia to give 3-fluoro-3-deazaadenosine analogs in excellent yield; in contrast, 6-c

  本文介绍了3,6-difluoro-3-deazapurine（4,7-difluoroimidazo [4,5- c ] pyridine）的制备方法。使用三种不同的核糖糖类似物在温和条件下将该新碱基糖基化。3，6-二氟-3-脱氮嘌呤核糖核苷类似物与液氨直接进行S N Ar胺化反应，以极好的收率得到3-氟-3-脱氮杂腺苷类似物。相反，在相似的反应条件下，6-氯-3-氟-3-脱氮嘌呤核苷是惰性的。
• Nucleoside derivatives for treating hepatitis C virus infection
  申请人：——

  公开号：US20040063658A1

  公开（公告）日：2004-04-01

  Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.

  本发明涉及用于治疗丙型肝炎病毒感染的化合物、组合物和方法。